Dacomitinib (CAS 1110813-31-4) is a high-purity pharmaceutical API classified as a potent pan-EGFR inhibitor, featuring a quinazoline-derived molecular structure designed for irreversible binding to EGFR family receptors (EGFR/HER1, HER2, HER4). Unlike reversible EGFR inhibitors, it forms covalent bonds with receptor tyrosine kinases, suppressing downstream signaling pathways that drive tumor cell proliferation, migration, and angiogenesis—delivering durable anticancer efficacy. This API presents as a white to pale yellow crystalline powder with excellent stability and solubility, supporting diverse formulation development.
It caters to the core needs of oncology drug manufacturers, targeted therapy developers, and precision medicine suppliers. Widely applied in developing treatments for non-small cell lung cancer (NSCLC) with EGFR mutations, it aligns with demand for novel, irreversible targeted anticancer therapies. Produced under strict GMP standards, each batch undergoes rigorous purity, crystal morphology, and bioactivity testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing precision oncology solutions, this Dacomitinib API serves as a critical raw material for advancing EGFR-targeted anticancer medication development.
